Novartis: inhibitor shows benefit in breast cancer trial
(CercleFinance.com) - Novartis' experimental inhibitor BYL719 showed benefit in patients with HR+/HER2- advanced breast cancer, the Swiss company said on Thursday.
A Phase III trial evaluating the investigational alpha-specific PI3K inhibitor has met its primary endpoint, showing an improvement in progression-free survival, the group said.
The study is evaluating BYL719, in combination with fulvestrant, compared to fulvestrant alone in hard-to-treat postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) PIK3CA-mutant advanced or metastatic breast cancer.
There are currently no approved PI3K inhibitors for HR+ advanced breast cancer, altough studies have established the role of PI3K in cancer progression.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
A Phase III trial evaluating the investigational alpha-specific PI3K inhibitor has met its primary endpoint, showing an improvement in progression-free survival, the group said.
The study is evaluating BYL719, in combination with fulvestrant, compared to fulvestrant alone in hard-to-treat postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) PIK3CA-mutant advanced or metastatic breast cancer.
There are currently no approved PI3K inhibitors for HR+ advanced breast cancer, altough studies have established the role of PI3K in cancer progression.
Copyright (c) 2018 CercleFinance.com. All rights reserved.